Country: Italy
Language: English
Source: HMA (Heads of Medicines Agencies)
pyriproxifen 1 %
Virbac S.A.
QP53BX
Premix for medicated feed
Other ectoparasiticides for systemic use
Dogs
2006-03-07
SPC RENEWAL final version April 2006 Dokument1 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT PYRIPROXYFEN 1% PREMIX FOR DOG VIRBAC. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Pyriproxyfen……………………………0.01 g Excipient Q.S. 1 g For a full list of excipients see point 6.1 3. PHARMACEUTICAL FORM Premix for medicated feed 4. CLINICAL PARTICULARS 4.1. TARGET SPECIES Dogs 4.2. INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Prevention of flea multiplication by sterilising the eggs 4.3. CONTRAINDICATIONS None known 4.4. SPECIAL WARNINGS FOR EACH TARGET SPECIES If there are several dogs in a same home, the treatment should be administered to all of them. As this feed contains pyriproxyfen, a medicinal product, dogs should not be given more feed than is recommended : i.e., do not exceed the recommended daily amount of 100 grams of medicated feed per 10 kg bodyweight per day. All animals in the home should be treated with a suitable flea control preparation, at the same time that the product is administered to the dogs. 4.5. SPECIAL PRECAUTIONS FOR USE I) SPECIAL PRECAUTIONS FOR USE IN ANIMALS If there is an existing flea infestation when the animal is treated or if there are occasional flea infestations during treatment, adult fleas must be eliminated wit h appropriate insecticidal medicines. This medicinal premix is intended for the manufacturing of solid medicinal foods and cannot be used as it is. The mixing rate of th Read the complete document